Evogene announces annual shareholder meeting

Evogene will hold its annual general meeting on Sept. 4, 2026 in Rehovot, Israel.

Shareholders will vote on competing board slates: a seven-member slate backed by the board or a four-member slate nominated by Pure Capital shareholders.

An amendment is proposed to lift authorized share capital by NIS 24 million to NIS 30 million, representing 150,000,000 ordinary shares.

A reverse share split framework is up for approval, allowing a ratio between 1-for-2 and 1-for-15 at the board’s discretion within 18 months.

Kost Forer Gabbay & Kasierer, an Ernst & Young member firm, is proposed for reappointment as independent auditor for 2026.